About this trial
Asthma is a chronic inflammatory airway disease associated with variable airflow limitation and persistent respiratory symptoms. Vitamin D has been proposed as a potential biomarker related to immune regulation, asthma control, pulmonary function, and oxidative stress balance.
This prospective cross-sectional observational study aims to investigate the association between serum 25-hydroxyvitamin D \[25(OH)D\] concentrations, asthma control, pulmonary function parameters, and erythrocyte oxidative stress biomarkers among Egyptian adults with bronchial asthma.
A total of 200 adult asthma patients will be recruited from Abbassia Chest Hospital, Cairo, Egypt. Participants will undergo clinical assessment, Asthma Control Test (ACT), post-bronchodilator spirometry, serum vitamin D measurement, and oxidative stress biomarker assessment including malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPx), and reduced glutathione (GSH).
Participants will be categorized according to serum 25(OH)D concentrations into vitamin D deficient, insufficient, and sufficient groups.
No intervention or treatment assignment will be performed.
5\. Detailed Description
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years.
Confirmed diagnosis of bronchial asthma.
Clinically stable at the time of assessment.
Availability of spirometry results.
Disqualifiers
Other chronic pulmonary diseases.
Active respiratory infection.
Malignancy.
Significant renal or hepatic disease.
Trial population
The study population will consist of 200 adult patients with confirmed bronchial asthma recruited from Abbassia Chest Hospital, Cairo, Egypt. Eligible participants will be adults aged ≥18 years with stable asthma at the time of assessment. Participants will be categorized according to serum 25-hydroxyvitamin D \[25(OH)D\] concentrations into vitamin D deficient (\<20 ng/mL), vitamin D insufficient (20-30 ng/mL), and vitamin D sufficient (\>30 ng/mL) groups. Clinical characteristics, asthma control, pulmonary function, serum vitamin D status, and erythrocyte oxidative stress biomarkers will be assessed during a single study visit.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Asthma Control Level Measured by Asthma Control Test (ACT) Score
Assessment of asthma control using the Asthma Control Test (ACT) questionnaire, reported as an ACT score ranging from 0 to 25 points.
Secondary outcomes
Pulmonary Function Parameters
FEV1 % predicted FVC % predicted FEV1/FVC ratio
Oxidative Stress Biomarkers
Malondialdehyde (MDA) Superoxide dismutase (SOD) Glutathione peroxidase (GPx) Reduced glutathione (GSH)
Serum Vitamin D Concentration
Serum 25-hydroxyvitamin D concentration (ng/mL)
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: